Trianex (triamcinolone acetonide)

The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence:

• Burning
• Itching
• Irritation
• Dryness
• Folliculitis
• Hypertrichosis
• Acneiform eruptions
• Hypopigmentation
• Perioral dermatitis
• Allergic contact dermatitis
• Maceration of the skin
• Secondary infection
• Skin atrophy
• Striae
• Miliaria

• Trianex 0.05% (triamcinolone acetonide) Ointment, USP is generally applied to the affected area as a thin fi lm from two to four times daily depending on the severity of the condition.
• Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions.
• If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.
• For external use only.
• Not for ophthalmic use.

• Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels.
• The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals.
• There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids.
• Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
• Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.
• It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk.
• Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.